Immunovia AB (publ)
IMMVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $90 | $139 | $455 |
| % Growth | -88.1% | -35.3% | -69.5% | – |
| Cost of Goods Sold | $36 | $2,116 | $0 | $0 |
| Gross Profit | $65 | $90 | $139 | $455 |
| % Margin | 607.8% | 100% | 100% | 100% |
| R&D Expenses | $0 | $727 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $19,792 | $17,313 | $29,216 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $25,116 | -$377 | $1,732 | $1,358 |
| Operating Expenses | $25,116 | $20,142 | $19,045 | $30,574 |
| Operating Income | -$25,051 | -$20,052 | -$18,906 | -$30,119 |
| % Margin | -234,230.9% | -22,280% | -13,601.4% | -6,619.6% |
| Other Income/Exp. Net | -$4,693 | -$20,999 | -$38,886 | $33,189 |
| Pre-Tax Income | -$29,744 | -$41,051 | -$57,792 | $3,070 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,150 | -$41,051 | -$57,792 | $3,070 |
| % Margin | -29,452% | -45,612.2% | -41,577% | 674.7% |
| EPS | -0.008 | -0.14 | -0.24 | 0.048 |
| % Growth | 94.1% | 41.7% | -599% | – |
| EPS Diluted | -0.008 | -0.14 | -0.24 | 0.048 |
| Weighted Avg Shares Out | 383,044 | 297,831 | 241,421 | 63,760 |
| Weighted Avg Shares Out Dil | 383,044 | 297,831 | 241,421 | 63,951 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $11 | $26 | $33,206 |
| Interest Expense | $4,705 | $21,011 | $38,912 | $17 |
| Depreciation & Amortization | $48 | $322 | $879 | $1,283 |
| EBITDA | -$2,604 | -$19,718 | -$18,001 | $4,370 |
| % Margin | -24,348.6% | -21,908.9% | -12,950.4% | 960.4% |